10-fold increase of hepatic total cholesterol, more impressive than the 5-fold increase in TG. Third, such hepatic cholesterol accumulation was associated with steatosis, an inflammatory cell infiltration and ballooning of hepatocytes, together with perisinusoidal fibrosis; these are collectively the key findings of NASH (ductular proliferation and extramedullary erythropoiesis were also observed, but are not features of human NASH). Liver histology was normal in low-responder opossums fed the same diet.
So the most salient feature of this novel animal model of NASH is that it does not depend solely on genetic predisposition (like db/db and ob/ob mice) nor on diet alone (e.g., 2% cholesterol HCHF diets in rats or mice). Rather, like humans with NASH (10, 19) , it depends on two factors: a genetically predisposed host, who becomes exposed to one or more environmental factors that were not the norm before 1980. In this case, the HCHF diet contained 0.7% cholesterol, considerably less than the 2% cholesterol diets (often with cholic acid) that are toxic to livers of rats and mice (2, 11, 16, 20, 22, 23) , not surprisingly as the amount of dietary cholesterol is roughly equivalent to 20 kg/day for humans (Ͼ100 hamburgers?) (11) .
These are not the first data that incriminate cholesterol as a potential mediator of lipotoxicity in NASH (1, 4, 11, 22, 25) . In fact, the few existing human lipidomic data are entirely consistent with one or more cholesterol fractions [free cholesterol (FC), oxysterols, cholesterol esters] associating with the NASH phenotype of NAFLD, in fact more consistently so than for any other lipid class (4, 25) . Thus Puri and colleagues (25) found that total cholesterol was higher in NASH livers than in NAFLD without NASH; free fatty acids (FFA) and other lipid fractions were not. Using nonquantitative fillipin fluorescence, Caballero et al. (4) also confirmed that FC is present in abundance in human NASH livers. Until recently, the favored "lipotoxic mediator" in NASH has been either FFA, or lysophosphatidylcholine, or other phospholipid metabolites (12) ; for example, exposing hepatocytes to palmitic acid causes cell death via formation of lysophosphatidylcholine (15) . This made sense because the dominant source of fatty acids in livers of obese patients with NASH is from lipolysis of peripheral tissues, such as adipose (7, 9) , whereas saturated FFA cause lipotoxic injury to many cell types, including those of hepatic lineage (15, 24) . However, an "inconvenient truth" is that there is no difference in hepatic FFA between NASH and not-NASH NAFLD in the few studies in which such data are available (1, 25) .
There is other evidence that cholesterol could be implicated in NASH pathogenesis, other than 2% cholesterol high-fat (HF) diet studies, which may, like methionine-and cholinedeficient mice that we popularized 16 yr ago (10) , really be a model of "toxic steatohepatitis". Llacuna et al. (20) recently demonstrated that 2% dietary cholesterol causes mitochondrial GSH depletion, rendering mice highly susceptible to ischemiareperfusion injury. Furthermore, Dutch workers from the lab-oratory of Hofker and Shiri-Svedlov identified a strong association between steatohepatitis and dietary cholesterol in humanized apolipoprotein E2 knock-in (ApoE2 ki ) and LDL receptor (LDLR Ϫ/Ϫ ) C57/Bl6 mice (33) . Feeding such mice a HF diet containing 0.2% cholesterol increases hepatic total cholesterol, with concomitant elevations in hepatic CD11b-positive cell infiltration and CD68 mRNA expression, as well as significant increases in hepatic monocyte chemotactic protein-1 and tumor necrosis factor gene expression (33) . Wouters et al. (34) subsequently demonstrated that administration of T0901317, a liver X receptor agonist, simultaneously lowered hepatic cholesterol content and CD11b cell recruitment in ApoE2 ki mice, despite T0901317-induced elevations in hepatic TG. Separately, the same workers demonstrated a role of macrophage modified LDL (oxidized and acetylated LDL) receptors in contributing to hepatic inflammation, apoptosis, and fibrosis. Specifically, hepatic inflammatory cell recruitment, apoptosis, and fibrosis are decreased in CD36 and macrophage scavenger receptor (Msr)-1 deficient (CD36
ϩ/ϩ /Msr1 ϩ/ϩ bone marrow controls (3) . These data suggest that macrophage-dependent uptake of modified LDL cholesterol contributes to NASH severity in the LDLR Ϫ/Ϫ model of NAFLD.
A limitation of the above studies is that the mice were generally not obese, diabetic, or insulin resistant (16), the latter being a sine qua non for human NASH (6, 7, 19, 21) . No such limitations are posed by Alms1 mutant (foz/foz) mice characterized in the authors' laboratory and now being used in several others (16 -18, 27, 28) . Foz/foz mice differ from ABCB4 mutant opossums in that the "genetic predisposition" that underlies NASH is not in lipid handling: it is in cilial anchoring to hypothalamic neurons, which causes an appetite defect and leptin resistance (13) . After early-onset obesity, foz/foz mice develop insulin resistance, diabetes, and dyslipidemia associated with hypoadiponectinemia (18), the metabolic accompaniments of human NASH (7, 19) . Like high-responder opossums, foz/foz mice on an appropriate strain background (NOD-B10 or C57/Bl6, but not Balb-c) develop fibrotic NASH (17, 18) , but only when fed a 0.2% cholesterol HF diet (18, 27) , again reflecting the need for both genetic and environmental factors in NASH pathogenesis.
In HF-fed foz/foz mice with NASH, hepatic total cholesterol is elevated 200-fold, an order of magnitude higher than the increase in TG and FFA, and FC is ϳ5-fold increased over both genotype and dietary controls (27) . We have been able to attribute the mechanism of such hepatic cholesterol accumulation to hyperinsulinemia, by showing directly that this is what induces sterol-regulatory element binding protein 2 (SREBP2) (27) . SREBP2 is also upregulated in human NASH livers (4). In turn, its activation upregulates hepatic cholesterol uptake via LDLR and suppresses cholesterol biotransformation to form bile acids (via CYPs7A1 and 27A1) and secretion into bile (via ABCG5/8 or ABCB11, the bile salt export pump) (27, 29) . Our laboratory has also shown that correcting liver cholesterol fractions (total, FC, oxysterols) by dietary restriction (27) or pharmacological therapy (28) reverses liver injury, with corresponding reversal of liver pathology from inflammation, apoptosis, hepatocyte ballooning, and fibrosis (NASH) back to simple steatosis. Conversely, other lipid fractions, such as TG, diacylglycerides, total, saturated, unsaturated, and individual FFA, and phospholipids do not change in response to the dietary and drug interventions that modulate disease phenotype (27, 28) .
In the study by Chan et al. (5), changes in hepatic gene expression provide clues to a different mechanism for disordered hepatic cholesterol turnover in opossums with NASH. Assuming that the ABCB4 mutation is what leads to hepatic cholesterol accumulation (there is no evidence of insulin resistance, and SREBP2 was not studied), one might expect compensatory suppression of cholesterol synthesis via its ratelimiting step of 3-hydroxy-3-methylglutaryl-CoA reductase, reduced hepatic cholesterol uptake, and stimulation of cholesterol biotransformation and canalicular pathways for secretion of cholesterol and bile acids. Instead, 3-hydroxy-3-methylglutaryl-CoA reductase mRNA levels were 3.8-fold higher in high responders than low responders (enzyme activity would have been of interest for this complexly regulated protein). On the other hand, LDLR mRNA values were lower in high responders, as was CYP27A1, which encodes the second pathway of cholesterol biotransformation to bile acids (values for CYP7A1 mRNA were not different). Also suppressed were genes involved in canalicular secretion of cholesterol [ABCG8, Niemann-Pick C1-like protein (NPC1L1), but not the bile salt export pump]. Without study of the regulatory proteins involved (SREBP2, liver X-receptor, farnesyl X-receptor, short heterodimeric partner, and liver receptor homolog 1), these data are incomplete [for a more comprehensive overview of hepatic cholesterol physiology, the reader is referred to a recent review (29) ]. However, the general observation accords with our findings in HF-fed foz/foz mice, that is, that physiological responses to hepatic cholesterol accumulation in disease situations can be paradoxical (apparently inappropriate) and are clearly not always sufficient to remove the hepatic cholesterol load. In the case of ABCB4 mutant opossums consuming a moderate-cholesterol, high-saturated-fat diet, this leads to "dysregulation" of hepatic cholesterol homeostasis that exacerbates cholesterol accumulation in the liver and also facilitates steatosis. The mechanisms for such dysregulation of cholesterol homeostasis in this and other models, and the way in which cholesterol causes liver injury, inflammation, and fibrosis should provide fascinating insights into NASH pathogenesis.
What else can we take away from this important study? First, there is an urgent need for an agreed set of pathological criteria for NASH in experimental studies if we are to rid journal pages of the irrelevant. In our view, we do not understand the objection as to why these should not be the same as for human NASH. If so, the present model would be one of the few acceptable ones for valid studies of NASH pathogenesis in intact animals, whereas purely dietary approaches in mice (including 2% cholesterol diets) rarely seem to cause the key features of hepatocyte ballooning and apoptosis, substantial mixed cell inflammation, and perisinusoidal fibrosis in 24 wk (16) . Second, the focus on human studies should be on relationships between the pathophysiological changes (such as insulin resistance), genetic and environmental determinants, with disease phenotype, and how this is linked to candidate lipotoxic molecules. Cholesterol is now a prime target. Third, this is the type of model in which to develop mechanism-based therapies rather than to repeat the numerous false leads in this area based on concepts of disease pathogenesis that may be flawed. Finally, it is high time that investigators and journal editors paid more attention to the possum and to other models of NASH that incorporate all three key elements of NASH pathogenesis: a genetically predisposed host, an altered environment, and resultant metabolic disorder. Run possum run!
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